Powering the future: a comprehensive review of battery energy storage systems

Global society is significantly speeding up the adoption of renewable energy sources and their integration into the current existing grid in order to counteract growing environmental problems, particularly the increased carbon dioxide emission of the last century. Renewable energy sources have a tremendous potential to reduce carbon dioxide emissions because they practically never produce any carbon dioxide or other pollutants. On the other hand, these energy sources are usually influenced by geographical location, weather, and other factors that are of stochastic nature. The battery energy storage system can be applied to store the energy produced by RESs and then utilized regularly and within limits as necessary to lessen the impact of the intermittent nature of renewable energy sources. The main purpose of the review paper is to present the current state of the art of battery energy storage systems and identify their advantages and disadvantages. At the same time, this helps researchers and engineers in the field to find out the most appropriate configuration for a particular application. This study offers a thorough analysis of the battery energy storage system with regard to battery chemistries, power electronics, and management approaches. This paper also offers a detailed analysis of battery energy storage system applications and investigates the shortcomings of the current best battery energy storage system architectures to pinpoint areas that require further study.This publication is part of the project TED2021-132864A-I00, funded by MCIN/ AEI/10.13039/501100011033 and by the European Union “NextGenerationEU”/PRTR”.Peer ReviewedPostprint (published version

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Gestión del conocimiento. Perspectiva multidisciplinaria. Volumen 9

El libro “Gestión del Conocimiento. Perspectiva Multidisciplinaria”, volumen 9, de la Colección Unión Global, es resultado de investigaciones. Los capítulos del libro, son resultados de investigaciones desarrolladas por sus autores. El libro es una publicación internacional, seriada, continua, arbitrada de acceso abierto a todas las áreas del conocimiento, que cuenta con el esfuerzo de investigadores de varios países del mundo, orientada a contribuir con procesos de gestión del conocimiento científico, tecnológico y humanístico que consoliden la transformación del conocimiento en diferentes escenarios, tanto organizacionales como universitarios, para el desarrollo de habilidades cognitivas del quehacer diario. La gestión del conocimiento es un camino para consolidar una plataforma en las empresas públicas o privadas, entidades educativas, organizaciones no gubernamentales, ya sea generando políticas para todas las jerarquías o un modelo de gestión para la administración, donde es fundamental articular el conocimiento, los trabajadores, directivos, el espacio de trabajo, hacia la creación de ambientes propicios para el desarrollo integral de las instituciones

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac

Gestión del conocimiento: perspectiva multidisciplinaria. Volumen 11

El libro “Gestión del Conocimiento. Perspectiva Multidisciplinaria”, Volumen 11, de la Colección Unión Global, es resultado de investigaciones. Los capítulos del libro, son resultados de investigaciones desarrolladas por sus autores. El libro cuenta con el apoyo de los grupos de investigación: Universidad Sur del Lago “Jesús María Semprúm” (UNESUR), Zulia – Venezuela; Universidad Politécnica Territorial de Falcón Alonso Gamero (UPTAG), Falcón – Venezuela; Universidad Politécnica Territorial de Mérida Kleber Ramírez (UPTM), Mérida – Venezuela; Universidad Guanajuato (UG) - Campus Celaya - Salvatierra - Cuerpo Académico de Biodesarrollo y Bioeconomía en las Organizaciones y Políticas Públicas (C.A.B.B.O.P.P), Guanajuato – México; Centro de Altos Estudios de Venezuela (CEALEVE), Zulia – Venezuela, Centro Integral de Formación Educativa Especializada del Sur (CIFE - SUR) - Zulia - Venezuela, Centro de Investigaciones Internacionales SAS (CIN), Antioquia - Colombia.y diferentes grupos de investigación del ámbito nacional e internacional que hoy se unen para estrechar vínculos investigativos, para que sus aportes científicos formen parte de los libros que se publiquen en formatos digital e impreso

Migració de funcionalitat d'assistent de pàrquing a plataforma embeguda

Projecte realitzat en col·laboració amb ADASENS AUTOMOTIVE[ANGLÈS] Migration to PC platform, and posterior migration to embedded hardware platform of an already existing functionality in privative platform.[CASTELLA] Migración a plataforma PC y posterior migración a plataforma hardware embebida de una funcionalidad existente en plataforma privativa.[CATALÀ] Migració a plataforma PC i posterior migració a plataforma hardware embeguda d'una funcionalitat existent en plataforma privativa

Migració de funcionalitat d'assistent de pàrquing a plataforma embeguda

Projecte realitzat en col·laboració amb ADASENS AUTOMOTIVE[ANGLÈS] Migration to PC platform, and posterior migration to embedded hardware platform of an already existing functionality in privative platform.[CASTELLA] Migración a plataforma PC y posterior migración a plataforma hardware embebida de una funcionalidad existente en plataforma privativa.[CATALÀ] Migració a plataforma PC i posterior migració a plataforma hardware embeguda d'una funcionalitat existent en plataforma privativa

Migració de funcionalitat d'assistent de pàrquing a plataforma embeguda

Projecte realitzat en col·laboració amb ADASENS AUTOMOTIVE[ANGLÈS] Migration to PC platform, and posterior migration to embedded hardware platform of an already existing functionality in privative platform.[CASTELLA] Migración a plataforma PC y posterior migración a plataforma hardware embebida de una funcionalidad existente en plataforma privativa.[CATALÀ] Migració a plataforma PC i posterior migració a plataforma hardware embeguda d'una funcionalitat existent en plataforma privativa

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.

Journal Article;BACKGROUND AND OBJECTIVE Significant controversy still exists about ritonavir-boosted protease inhibitor monotherapy (mtPI/rtv) as a simplification strategy that is used up to now to treat patients that have not experienced previous virological failure (VF) while on protease inhibitor (PI) -based regimens. We have evaluated the effectiveness of two mtPI/rtv regimens in an actual clinical practice setting, including patients that had experienced previous VF with PI-based regimens. METHODS This retrospective study analyzed 1060 HIV-infected patients with undetectable viremia that were switched to lopinavir/ritonavir or darunavir/ritonavir monotherapy. In cases in which the patient had previously experienced VF while on a PI-based regimen, the lack of major HIV protease resistance mutations to lopinavir or darunavir, respectively, was mandatory. The primary endpoint of this study was the percentage of participants with virological suppression after 96 weeks according to intention-to-treat analysis (non-complete/missing = failure). RESULTS A total of 1060 patients were analyzed, including 205 with previous VF while on PI-based regimens, 90 of whom were on complex therapies due to extensive resistance. The rates of treatment effectiveness (intention-to-treat analysis) and virological efficacy (on-treatment analysis) at week 96 were 79.3% (CI95, 76.8-81.8) and 91.5% (CI95, 89.6-93.4), respectively. No relationships were found between VF and earlier VF while on PI-based regimens, the presence of major or minor protease resistance mutations, the previous time on viral suppression, CD4+ T-cell nadir, and HCV-coinfection. Genotypic resistance tests were available in 49 out of the 74 patients with VFs and only four patients presented new major protease resistance mutations. CONCLUSION Switching to mtPI/rtv achieves sustained virological control in most patients, even in those with previous VF on PI-based regimens as long as no major resistance mutations are present for the administered drug.Ye